However on the contrary there were few studies which revealed that although sitagliptin significantly improved hemodynamic and metabolic parameters in Tyupe-2 diabetic patients but failed to improved inflammation marked by reduction of CRP.18-20 The probable reason in these studies was that some of the patients have already concurrent illness such as dyslipidemia, obesity, hypertension and coronary artery disease. Here, CRP is linked to metabolic syndrome.